Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 3/20 | 0.70 |
| ▸ | CCR1 | P32246 | 1/20 | 0.57 |
| ▸ | CCR8 | P51685 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.47 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19603066 | 0.87 | METAP2 (0.59) | METAP2KDM4EKMT2APLAUNCF1 | |
| SCHEMBL21767732 | 0.87 | METAP2 (0.63) | METAP2KDM4EKMT2APLAUNCF1 | |
| SCHEMBL15452284 | 0.85 | CCR1 (0.73) | METAP2CCR1CCR8KDM4EKMT2A | |
| 8-Hydroxy Quinaldine SCHEMBL29483489 | 0.83 | METAP2 (1.00) | METAP2CCR1KDM4EKMT2APLAU | |
| 8-Hydroxy Quinaldine SCHEMBL297247 | 0.83 | METAP2 (1.00) | METAP2CCR1KDM4EKMT2APLAU | |
| 8-Hydroxy Quinaldine SCHEMBL9154369 | 0.81 | METAP2 (0.96) | METAP2CCR1KDM4EKMT2APLAU | |
| 8-Hydroxy Quinaldine SCHEMBL22734876 | 0.81 | METAP2 (0.96) | METAP2CCR1KDM4EKMT2APLAU | |
| 8-Hydroxy Quinaldine SCHEMBL4304584 | 0.81 | METAP2 (0.96) | METAP2CCR1KDM4EKMT2APLAU | |
| 8-Hydroxy Quinaldine SCHEMBL7179747 | 0.81 | METAP2 (0.96) | METAP2CCR1KDM4EKMT2APLAU | |
| 8-Hydroxy Quinaldine SCHEMBL5089361 | 0.81 | METAP2 (0.96) | METAP2CCR1KDM4EKMT2APLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | SIERRA SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-04-02 | — | — | US | disclosed |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-01-22 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-7619091-B2 | Treating nervous system disorders such as mild cognitive impairment, Alzheimer's disease or dementia associated with Down syndrome; e.g. use of 5,7-dichloro-8-hydroxy-2-(2-pyridyl)-quinoline (PBT 1052) | PRANA BIOTECHNOLOGY LIMITED (AU) | 2009-11-17 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | METAP2 370/4885CCR1 3056/4885CCR8 2432/4885 |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | METAP2 1832/4885CCR1 3231/4885CCR8 1054/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | METAP2 1832/4885CCR1 3231/4885CCR8 1054/4885 |
| US-11701374-B1 | 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression | TERT, TERF2, RNGTT | METAP2 1330/4885CCR1 4654/4885CCR8 2028/4885 |
| US-20150025108-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | METAP2 1832/4885CCR1 3231/4885CCR8 1054/4885 |
| US-20150094334-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | METAP2 1832/4885CCR1 3231/4885CCR8 1054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.